Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMALXYR)

• Drug Name: PMID29671355-Compound-13 Drug Info
• Cross-matching ID:
  PubChem CID: 71811260
  TTD Drug ID: DMALXYR

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase 6 (HDAC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citarinostat	DMQLODU	Multiple myeloma	2A83	Phase 1	[2]
KA2507	DMW0H9Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Histone deacetylase 8 (HDAC8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NBM-BMX	DM5OWXA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PMID29671355-Compound-62	DMWRS34	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-43	DMVPMWJ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-25	DMPV0KZ	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-21	DMPJN0M	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-31	DM3H78D	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-56	DM0VBMI	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-67	DM1RPL4	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-23	DMUBOEX	N. A.	N. A.	Patented	[1]
PMID29671355-Compound-44	DM80A3V	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[4]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[5]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[6]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[7]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[8]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[9]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[10]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[4]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[1]
Histone deacetylase 6 (HDAC6)	TT5ZKDI	HDAC6_HUMAN	Inhibitor	[1]
Histone deacetylase 8 (HDAC8)	TTT6LFV	HDAC8_HUMAN	Inhibitor	[1]

References

• [1] HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
• [4] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [8] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [9] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [10] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [11] 2011 Pipeline of 4SC AG.